Besides the fact that WT induced greater VEGF expression, angiogenesis, and walking capacity in patients with PAD, the key novelty of the present study was the corresponding increase in miRNA-126 and PI3KR2, the target of miRNA-126, suggesting the participation of miRNA-126 in the VEGF signaling pathway of PI3K/Akt/eNOS. This evidence concerns the gene VEGFA and peripheral arterial disease.